Invention Grant
- Patent Title: Anti-VWF D'D3 single-domain antibodies fuse to clotting factors
-
Application No.: US16818463Application Date: 2020-03-13
-
Publication No.: US11560436B2Publication Date: 2023-01-24
- Inventor: Petrus Lenting , Gabriel Ayme , Cecile Denis , Olivier Christophe
- Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITE PARIS-SACLAY
- Applicant Address: FR Paris; FR Saint Aubin
- Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),UNIVERSITE PARIS-SACLAY
- Current Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),UNIVERSITE PARIS-SACLAY
- Current Assignee Address: FR Paris; FR Saint Aubin
- Agency: WC&F IP
- Priority: EP16305071 20160126
- Main IPC: C07K16/36
- IPC: C07K16/36 ; C07K14/755 ; C07K14/745 ; A61P7/04 ; A61K39/00 ; C12N15/62
Abstract:
The invention relates to isolated single-domain antibodies (sdAb) directed against von Willebrand Factor (VWF) D′D3 domain and chimeric polypeptides comprising thereof such as blood clotting factors and their uses in therapy such as in the prevention and treatment of hemostatic disorders. The invention also relates to a method of extending or increasing half-life of a therapeutic polypeptide comprising a step of adding to the polypeptide sequence of said therapeutic polypeptide at least one sdAb directed against VWF D′D3 domain.
Public/Granted literature
- US20200207869A1 ANTI-VWF D'D3 SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF Public/Granted day:2020-07-02
Information query
